Literature DB >> 7647968

Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.

J H Guh1, S C Chueh, F N Ko, C M Teng.   

Abstract

1. The effects of various alpha 1-adrenoceptor antagonists and nifedipine on tension responses of human prostate to electrical field stimulation were evaluated in this study. 2. Prazosin (3 x 10(-10) to 10(-8) M) and 5-methyl-urapidil (10(-9) to 3 x 10(-8) M) blocked concentration-dependently the tension responses to electrical field stimulation and completely abolished them in the maximal concentrations (10(-8) M and 3 x 10(-8) M, respectively); in contrast, chloroethylclonidine (CEC), in the maximal concentration of 100 microM, blocked these effects by only 50%. 3. The contractile responses of rat vas deferens and spleen to exogenously-applied alpha 1-adrenoceptor agonists were competitively inhibited by prazosin and 5-methyl-urapidil; in addition, the pA2 values were calculated and the relative potencies with reference to prazosin were obtained. The relative potency of 5-methyl-urapidil in human prostate (0.105) was close to that in rat vas deferens (0.257), which contains primarily putative alpha 1A-adrenoceptors. However, it was much more than that in rat spleen (0.011), which contains primarily putative alpha 1B-adrenoceptors. 4. Nifedipine (10(-8) to 10(-6) M) inhibited concentration-dependently the contractile responses to electrical field stimulation in human prostate; in addition, the inhibition percentages were similar to those to exogenously-applied noradrenaline in rat vas deferens. In contrast, CEC (10 microM), which almost flattened the concentration-response curve of the rat spleen to phenylephrine, only partially inhibited (by 33.1%) the nerve-mediated contraction of human prostate. 5. The involvement of prejunctional alpha 2-adrenoceptors situated on the sympathetic nerve terminals of human prostate was also examined. Clonidine (3 x 10-9 to 3 x 10- M) blocked concentration-dependently the contractile response to electrical field stimulation of human prostate and this inhibitory effect was reversed by yohimbine (10-7 M). Additionally, the inhibitory effect of CEC (3 x 10-6 to 3 x 10-4 M)to the nerve-mediated contraction was also partially reversed by yohimbine (10-7 M).6. It is suggested that the putative czA-adrenoceptors in human prostate may be functionally confined to the synaptic region whereas only minor populations of the putative alpha 1B- and/or alpha 1c-adrenoceptors exist in this region.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647968      PMCID: PMC1908749          DOI: 10.1111/j.1476-5381.1995.tb16331.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype.

Authors:  D A Schwinn; J W Lomasney
Journal:  Eur J Pharmacol       Date:  1992-12-01       Impact factor: 4.432

2.  Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.

Authors:  A Jardin; H Bensadoun; M C Delauche-Cavallier; P Attali
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

3.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5.

Authors:  J W Lomasney; S Cotecchia; W Lorenz; W Y Leung; D A Schwinn; T L Yang-Feng; M Brownstein; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

4.  Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs.

Authors:  D Y Li; D R Varma; S Chemtob
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Alpha 1 adrenoceptor subtypes in the human prostate.

Authors:  H Lepor; R Tang; S Meretyk; E Shapiro
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

6.  Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen.

Authors:  R Aboud; M Shafii; J R Docherty
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

7.  Species heterogeneity of hepatic alpha 1-adrenoceptors: alpha 1A-, alpha 1B- and alpha 1C-subtypes.

Authors:  J A García-Sáinz; M T Romero-Avila; R Alcántara Hernández; M Macias-Silva; A Olivares-Reyes; C González-Espinosa
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

8.  Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes.

Authors:  M C Michel; J Kerker; T A Branchek; C Forray
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

9.  Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.

Authors:  B A Kenny; A M Naylor; P M Greengrass; M J Russell; S J Friend; A M Read; M G Wyllie
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

10.  Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man.

Authors:  R Testa; L Guarneri; M Ibba; G Strada; E Poggesi; C Taddei; I Simonazzi; A Leonardi
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

View more
  8 in total

1.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Alpha1-adrenoceptors are required for normal male sexual function.

Authors:  A Sanbe; Y Tanaka; Y Fujiwara; H Tsumura; J Yamauchi; S Cotecchia; K Koike; G Tsujimoto; A Tanoue
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 3.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery.

Authors:  W B Stam; P H Van der Graaf; P R Saxena
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Noradrenergic vasoconstriction of pig prostatic small arteries.

Authors:  Paz Recio; Luis M Orensanz; María Pilar Martínez; Jorge Navarro-Dorado; Salvador Bustamante; Albino García-Sacristán; Dolores Prieto; Medardo Hernández
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 6.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

7.  Ouabain-induced increases in resting tone of human hyperplastic prostate following repeated noradrenaline and electrical field stimulation.

Authors:  J H Guh; F N Ko; S C Chueh; M K Lai; C M Teng
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 8.  Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression.

Authors:  Carl W White; Jin Han Xie; Sabatino Ventura
Journal:  Organogenesis       Date:  2013-05-14       Impact factor: 2.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.